Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD.

Inflammatory bowel diseases - 1 Feb 2015

Kalman Richard S, Hartshorn Kevan, Farraye Francis A

Abstract excerpt

The medical treatment for inflammatory bowel disease (IBD) has improved over the past 20 years. Although the routine use of immunomodulators and biologic agents in the treatment of IBD in the modern era has been a great achievement, these medicines are associated with rare but serious adverse events. In addition to the infectious complications, there are data to suggest that some of these agents are associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Products
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunologic Factors

Share to Inflammatory Bowel Diseases

Share to Neoplasms

Share to Precision Medicine

Source

Identifiers

PMID: 25251059
DOI: 10.1097/MIB.0000000000000211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD.PMID 25251059Read ↗

Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort.Semantic proximity Read ↗

Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study.Semantic proximity Read ↗

Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project.Semantic proximity Read ↗

Has the risk of colorectal cancer in inflammatory bowel disease decreased?Semantic proximity Read ↗

Case Report: Malignant melanoma in a patient with Crohn’s disease treated with ustekinumabSemantic proximity Read ↗

A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists.Semantic proximity Read ↗

The Oncology: Disease Modifying Anti-Rheumatic Drug Interface: A Cross-Specialty ReviewSemantic proximity Read ↗

Prevalence and relative risk of malignancy in relatives of inflammatory bowel disease patients and control subjects.Semantic proximity Read ↗

Review article: practical management of inflammatory bowel disease patients taking immunomodulators.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.